FDA announces updated draft guidance to assist food facilities in prevention of allergen cross-contact and proper labeling of food allergens, along with discouraging intentional addition of sesame to food products for compliance

Sample article from our Health Care Sector

September 26, 2023 (press release) –

Draft Guidance Provides Examples of Ways Manufacturers Can Significantly Minimize or Prevent Allergen Cross-Contact and Undeclared Allergens

Today, the U.S. Food and Drug Administration announced updated draft guidance designed to help food facilities comply with the requirements for current good manufacturing practices (CGMPs) and preventive controls for human food. In particular, the new chapter on food allergens outlines ways to ensure protection of food from major food allergen cross-contact and to ensure that the finished food is properly labeled with respect to the major food allergens.

Millions of Americans have food allergies and may experience adverse reactions to products that contain food allergens. While many allergic reactions may involve only mild symptoms, some are severe and may even be life-threatening. Earlier this year, sesame was added as the ninth major food allergen when the Food Allergy Safety, Treatment, Education, and Research (FASTER) Act became effective on Jan. 1. This means that sesame, when present in a food, is now required to be disclosed on food labels and firms need to implement controls to significantly minimize or prevent sesame allergen cross-contact.

With the passage of the FASTER Act, the FDA and families with sesame-allergic members hoped that it would become easier for those allergic to sesame to feel more confident in their food choices with the clear label declaration of sesame. However, some manufacturers are intentionally adding sesame to products that previously did not contain sesame and are labeling the products to indicate its presence, rather than take appropriate measures to minimize or prevent cross-contact. This keeps manufacturers in compliance with the law for disclosing the presence of a major food allergen. However, it also limits options for consumers who are allergic to sesame, a result the FDA does not support. The FDA is encouraging industry to follow the draft guidance on ways to significantly minimize or prevent allergen cross-contact and undeclared allergens and review the examples provided--rather than intentionally adding sesame to their products to comply with the law. 

“The FDA is looking for opportunities that could help consumers who are allergic to sesame and other major food allergens find foods that are safe for them to consume. We encourage manufacturers to follow the guidelines in the draft guidance updates released today to prevent allergen cross-contact and ensure proper labeling,” said FDA Commissioner Robert M. Califf, M.D.  “We recognize there are challenges with ensuring products are free of allergens and we are engaging with stakeholders on this issue. The agency is interested in finding solutions, within our authorities, that meet the needs of consumers with food allergies. Updating this draft guidance with the new allergen chapter provides one tool to help manufacturers meet this goal.” 

More Information About the Updates
Chapter 11—Food Allergen Program and Chapter 16—Acidified Foods—are among the chapters that have been added since the draft guidance, Hazard Analysis and Risk-Based Preventive Controls for Human Food, was first issued in 2016.

Chapter 11—Food Allergen Program—explains how to establish and implement a food allergen program that ensures protection of food from major food allergen cross-contact and that the finished food is properly labeled with respect to the major food allergens. It provides many examples of ways to significantly minimize or prevent allergen cross-contact and undeclared allergens using CGMPs and preventive controls. Labeling errors are the cause of most FDA food allergen recalls, and Chapter 11 includes guidance on how to monitor or verify that the food allergens are properly declared as required and the correct label is used for the product. 

The chapter also discusses circumstances in which, despite adherence to appropriate CGMPs and preventive controls, allergen presence due to cross-contact cannot be completely avoided and options a firm can consider, including the voluntary use of allergen advisory statements when appropriate. The chapter complements the FDA’s recently released Draft Compliance Policy Guide on Major Food Allergen Labeling and Cross-Contact, which reflects the agency’s risk-based and science-based approach for the evaluation of potential allergen violations. 

Chapter 16—Acidified Foods—applies to manufacturers, processors or packers of acidified foods (such as some processed sauces, beans, cucumbers or cabbage that have an overall pH of 4.6 or below). It explains how these manufacturers can use procedures, practices and processes that they have established to meet requirements in the acidified foods regulations to satisfy requirements under the preventive controls for human foods rule. 

Related Information

  • Constituent Update on the New Chapters of Draft Guidance for Preventive Controls
  • FDA Voices: An Update on Sesame Allergen Labeling on Food Packages
  • Allergic to Sesame? Food Labels Now Must List Sesame as an Allergen | FDA
  • FASTER Act Video for Food Industry and Other Stakeholders
  • Food Safety Modernization Act (FSMA) | FDA
  • FSMA Final Rule for Preventive Controls for Human Food | FDA
  • FSMA Technical Assistance Network (TAN) | FDA

###

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Inquiries
Media:
 Enrico Dinges
 240-620-9293
Consumer:
 888-INFO-FDA

 

 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.